Literature DB >> 8846414

Expression of B1 kinin receptors mediating paw edema and formalin-induced nociception. Modulation by glucocorticoids.

M M Campos1, L V Mata, J B Calixto.   

Abstract

Bradykinin (BK) and Tyr8-BK induced graded rat paw edema with EC50 values of 1.9 and 1.1 nmol/paw, while des-Arg9-BK (DABK, up to 300 nmol/paw) was marginally effective. Tyr8-BK, but not DABK, also caused a dose-related increase in mouse paw edema, with an EC50 of 1.3 nmol/paw. The response to Tyr8-BK (10 nmol/paw) in rat paw edema was antagonized by B2 receptor antagonists (HOE-140 or NPC 17731, 30 nmol/paw) but not by the B1 antagonist des-Arg9[Leu8]BK (DALBK, 100 nmol/paw). Daily intraplantar injections of Tyr8-BK (10 nmol/paw) for 7 days caused progressive desensitization (D) of edema in sham-operated and adrenalectomized Wistar rats. DABK (100 nmol/paw) caused marked paw edema in D paws from both groups, which was inhibited by DALBK (100 nmol/paw) and by dexamethasone (0.5mg/kg, s.c.). Systemic injection of lipopolysaccharide (10 micrograms/mouse, 24 h prior) potentiated the first and second phases of Formalin-induced pain but had no effect on paw edema. Coinjection of DABK (2-22 nmol/paw) with low doses of Formalin in lipopolysaccharide-treated mice, which had no effect on naive animals, dose dependently potentiated both phases of Formalin-induced pain but did not modify paw edema. These effects were antagonized by DALBK with ID50 values of 21.9 (first phase) and 64.1 (second phase) nmol/paw. Thus, both progressive desensitization of B2 receptors and systemic treatment with lipopolysaccharide induce a glucocorticoid-sensitive upregulation of B1 receptors mediating paw edema in the rat and Formalin-induced nociception in mice. These results suggest that induction of upregulation of B1 receptors may play important roles in controlling inflammatory processes and hyperalgesia.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8846414     DOI: 10.1139/y95-110

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  6 in total

Review 1.  Kinin B1 receptors: key G-protein-coupled receptors and their role in inflammatory and painful processes.

Authors:  João B Calixto; Rodrigo Medeiros; Elizabeth S Fernandes; Juliano Ferreira; Daniela A Cabrini; Maria M Campos
Journal:  Br J Pharmacol       Date:  2004-11-01       Impact factor: 8.739

2.  Antihyperalgesic activity of a novel nonpeptide bradykinin B1 receptor antagonist in transgenic mice expressing the human B1 receptor.

Authors:  Alyson Fox; Satbir Kaur; Bifang Li; Moh Panesar; Uma Saha; Clare Davis; Ilaria Dragoni; Sian Colley; Tim Ritchie; Stuart Bevan; Gillian Burgess; Peter McIntyre
Journal:  Br J Pharmacol       Date:  2005-04       Impact factor: 8.739

3.  Absence of ligand-induced regulation of kinin receptor expression in the rabbit.

Authors:  T Sabourin; K Guay; S Houle; J Bouthillier; D R Bachvarov; A Adam; F Marceau
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

4.  Anti-inflammatory and gastromucosal protective effects of Calotropis procera (Asclepiadaceae) stem bark.

Authors:  Nagesh Tour; Gokul Talele
Journal:  J Nat Med       Date:  2011-03-15       Impact factor: 2.343

5.  The role of kinin B1 and B2 receptors in the scratching behaviour induced by proteinase-activated receptor-2 agonists in mice.

Authors:  Robson Costa; Marianne N Manjavachi; Emerson M Motta; Denise M Marotta; Luiz Juliano; Hugo A Torres; João B Pesquero; João B Calixto
Journal:  Br J Pharmacol       Date:  2010-01-08       Impact factor: 8.739

6.  Evaluation of anti-inflammatory and gastric anti-ulcer activity of Phyllanthus niruri L. (Euphorbiaceae) leaves in experimental rats.

Authors:  Ronia Mostofa; Shanta Ahmed; Mst Marium Begum; Md Sohanur Rahman; Taslima Begum; Siraj Uddin Ahmed; Riazul Haque Tuhin; Munny Das; Amir Hossain; Manju Sharma; Rayhana Begum
Journal:  BMC Complement Altern Med       Date:  2017-05-16       Impact factor: 3.659

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.